A Prospective Study of Algorithm-based Screening in Patients With Glycemically Defined New Onset Hyperglycemia and Diabetes to Evaluate Risk for and Earlier Detection of Pancreatic Ductal Adenocarcinoma (Early Detection Initiative (EDI) for Pancreatic Cancer)

• Patient must have given institutional consent for minimal risk studies.

• Patient must be ≥50 and ≤85 years of age at the time of diagnosis \[index date Parameters of Diabetes Mellitus (PDM)\].

• Patient must have index weight and left-window weight values available in electronic medical record (EMR).

• Patient must have hyperglycemia and/or diabetes as one of the following (all glycemic parameters, except for HbA1c, must be measured in an outpatient setting):

⁃ A. Glycated hemoglobin (HbA1c) ≥ 6.5%

⁃ OR

⁃ B. Any (2) PDMs on consecutive (≤90 days between PDMs) or simultaneous testing:

• Fasting Blood Glucose (FBG) ≥126 mg/dl

• Glycated hemoglobin (HbA1c) ≥ 6.5%

• Random Blood Glucose (RBG) ≥200 mg/dl

• 2 hour Post Glucose (PG) ≥ 200mg (11.1 mmol/L) during oral glucose tolerance test (OGTT)

⁃ OR

⁃ C. Any one (1) PDM present followed by an anti- diabetes medication ≤90 days after the index PDM date

• Patient must have ≥1 glycemic parameter measured in the past 91-548 days prior to the index PDM date (Left Window) without meeting inclusion criteria A, B, or C.

• For Intervention Sites, patients must meet inclusion criteria A, B, or C ≤90 days prior to enrollment.